Cargando…

Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance

Multiclass high-level transmitted HIV drug resistance is uncommon, and the selection of the optimal initial antiretroviral drug regimen may be challenging. We report a case of extensive transmitted multiclass resistance successfully treated with dolutegravir, tenofovir, and emtricitabine even though...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagami, Ellen H, Thakarar, Kinna, Sax, Paul E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802795/
https://www.ncbi.nlm.nih.gov/pubmed/35111871
http://dx.doi.org/10.1093/ofid/ofab648
_version_ 1784642746219233280
author Nagami, Ellen H
Thakarar, Kinna
Sax, Paul E
author_facet Nagami, Ellen H
Thakarar, Kinna
Sax, Paul E
author_sort Nagami, Ellen H
collection PubMed
description Multiclass high-level transmitted HIV drug resistance is uncommon, and the selection of the optimal initial antiretroviral drug regimen may be challenging. We report a case of extensive transmitted multiclass resistance successfully treated with dolutegravir, tenofovir, and emtricitabine even though the baseline genotype demonstrated full susceptibility to only 1 drug class, integrase strand transfer inhibitors. Our case highlights both the high resistance barrier of dolutegravir and the residual antiviral activity of nucleoside reverse transcriptase inhibitors despite extensive resistance on genotype.
format Online
Article
Text
id pubmed-8802795
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-88027952022-02-01 Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance Nagami, Ellen H Thakarar, Kinna Sax, Paul E Open Forum Infect Dis Novel ID Cases Multiclass high-level transmitted HIV drug resistance is uncommon, and the selection of the optimal initial antiretroviral drug regimen may be challenging. We report a case of extensive transmitted multiclass resistance successfully treated with dolutegravir, tenofovir, and emtricitabine even though the baseline genotype demonstrated full susceptibility to only 1 drug class, integrase strand transfer inhibitors. Our case highlights both the high resistance barrier of dolutegravir and the residual antiviral activity of nucleoside reverse transcriptase inhibitors despite extensive resistance on genotype. Oxford University Press 2021-12-24 /pmc/articles/PMC8802795/ /pubmed/35111871 http://dx.doi.org/10.1093/ofid/ofab648 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Novel ID Cases
Nagami, Ellen H
Thakarar, Kinna
Sax, Paul E
Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance
title Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance
title_full Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance
title_fullStr Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance
title_full_unstemmed Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance
title_short Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance
title_sort sustained hiv viral suppression with dolutegravir, tenofovir, and emtricitabine as initial therapy despite high-level transmitted multiclass resistance
topic Novel ID Cases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802795/
https://www.ncbi.nlm.nih.gov/pubmed/35111871
http://dx.doi.org/10.1093/ofid/ofab648
work_keys_str_mv AT nagamiellenh sustainedhivviralsuppressionwithdolutegravirtenofovirandemtricitabineasinitialtherapydespitehighleveltransmittedmulticlassresistance
AT thakararkinna sustainedhivviralsuppressionwithdolutegravirtenofovirandemtricitabineasinitialtherapydespitehighleveltransmittedmulticlassresistance
AT saxpaule sustainedhivviralsuppressionwithdolutegravirtenofovirandemtricitabineasinitialtherapydespitehighleveltransmittedmulticlassresistance